Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid® OAD)

Journal of Opioid Management

Volumn 3, Issue 5, 2007, Pages 273-280

  Fishman, Ritchard L ^a   Kistler, Charles James ^b   Ellerbusch, Michael T ^c   Aparicio, Raul Tomas ^d   Swami, Sharad S ^e   Shirley, Mark E ^f   Jain, Adesh K ^g   Fortier, Louise ^h   Robertson, Sybil ^h   Bouchard, Sylvie ^h  

^a Remington Davis ^*

^b Remington Davis   (United States)

^c Capstone Clinical Trials   (United States)

^d Renstar Medical Research   (United States)

^e Prime Care Clinical Research   (United States)

^f Heartland Clinical Research Center   (United States)

^g Medical Research Institute   (United States)

^h Labopharm Inc   (Canada)

Author keywords

Analgesia; Controlled release; Osteoarthritis; Pain; Tramadol

Indexed keywords

CONTRAMID; PLACEBO; TRAMADOL; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GASTRITIS; HUMAN; HYPERHIDROSIS; INSOMNIA; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT DURATION; VERTIGO; VOMITING; XEROSTOMIA;

EID: 37249065725     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2007.0015     Document Type: Article

References (30)

1. World Health Organization: Cancer Pain Relief. Geneva: WHO, 1986.
2. American Heart Association: AHA statement recommends doctors change approach to prescribing pain relievers for patients with or at risk for heart disease. AHA Statement, 02/26/2007. Available at http://www.heart.org/presenter.jhtml?identifier=3045689. Accessed July 2007.
3. Ricci JA, Stewart WF, Chee E, et al.: Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum. 2005; 53: 673-681.
4. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000; 43: 1905-1915.
5. Bradley JD, Brandt KD, Katz BP, et al.: Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. New Engl J Med. 1991; 325: 87-91.
6. Brandt KD: Osteoarthritis. In Isselbacher KJ, Martin JB, Braunwald E, et al. (eds.): Harrison's Principles of Internal Medicine. 13th ed. New York: McGraw-Hill, 1994: 1692-1698.
7. Brandt KD: Management of osteoarthritis. In Kelley WN, Harris ED, Ruddy S, et al. (eds.): Textbook of Rheumatology. 4th ed. Philadelphia: WB Saunders, 1993: 1385-1399.
8. Griffin MR, Piper JM, Daugherty JR, et al.: Nonsteroidal anti-inflammatory drug use and increased risk of peptic ulcer disease in elderly persons. Ann Intern Med. 1991; 114: 257-263.
9. Roth SH: Nonsteroidal anti-inflammatory drugs: Gastropathy, deaths, and medical practice. Ann Intern Med. 1991; 114: 257-263.
10. Roth SH, Bennett RE: Nonsteroidal anti-inflammatory drug gastropathy: Recognition and response. Arch Intern Med. 1988; 109: 353-354.
11. Schafer AI: Effects of nonsteroidal anti-inflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 1995; 35: 209-219.
12. Raffa RB, Freidrichs E: The basic science aspect of Tramadol hydrochloride. Pain Rev. 1996; 3: 249-271.
13. Reimann W, Schneider F: Induction of 5-hydroxytriptamine release by Tramadol, fenfluramine and reserpine. Eur J Pharmacol. 1998; 349(2/ 3): 199-203.
14. Grond S, Sablotzki A: Clinical pharmacology of Tramadol. Clin Pharmacokinet. 2004; 43: 879-923.
15. Grond S, Zech D, Lynch J, et al.: Tramadol: A weak opioid for relief of cancer pain. Pain Clinic. 1992; 5: 241-247.
16. Harati Y, Gooch C, Swensen M, et al.: Double-blind randomized trial of tramadol in the treatment of the pain of diabetic neuropathy. Neurology. 1998; 50: 1842-1846.
17. Sindrup SH, Andersen G, Madsen C, et al.: Tramadol relieves pain and allodynia in polyneuropathy: A randomized double-blind controlled trial. Pain. 1999; 83: 85-90.
18. Jensen EM, Ginsberg F: Tramadol versus dextropropoxyphene in the treatment of osteoarthritis: A short term double-blind study. Drug Invest. 1994; 8: 211-218.
19. Fleischmann RM, Caldwell JR, Roth SH, et al.: Tramadol for the treatment of joint pain associated with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Curr Ther Res. 2001; 62: 113-128.
20. Roth SH: Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol. 1998; 25: 1358-1363.
21. Cossman M, Kohnene C, Langford R, et al.: Tolerance and safety of tramadol use: Results of international studies and data from drug surveillance. Drugs. 1997; 53(suppl 2): 50-62.
22. Rahmouni M, Gervais S, Karhu D, et al.: Development and clinical evaluation of a novel once-a-day tramadol formulation. In the 32nd Annual Meeting and Exposition of the Controlled Release Society, Miami Beach, Florida, June 18-22, 2005.
23. Topalgic® LP: Vidal 2006: Le Dictionnaire. 82e ed. Paris: Editions du Vidal, 2006: 2102-2103.
24. Karhu D, Bouchard S: Comparative bioavailability of Tramadol Contramid® once-a-day and tramadol immediate-release tablets. In The American Academy of Pain Medicine (AAPM), 23rd Annual Meeting, New Orleans, USA. Poster 145, 2007.
25. Karhu D, Bouchard S: Pharmacokinetic evaluation of a novel once-a-day tramadol hydrochloride formulation. In American College of Clinical Pharmacology 34th Annual Meeting, Rockville, MD, Sep 11, 2005.
26. Manek NJ, Lane NE: Osteoarthritis: Current concepts in diagnosis and management. Am Fam Physician. 2000; 61: 1795-1804.
27. Mongin G, Yakusevich V, Kope A, et al.: Efficacy and safety of a novel once-daily tablet formulation of Tramadol. Clin Drug Investig. 2004; 24: 545-558.
28. Lenaerts V, Moussa I, Dumoulin Y, et al.: Cross-linked high amylose starch for controlled release of drugs: Recent advances. J Control Release. 1998; 53(1-3): 225-234.
29. Hancock BC, Carlson GT, Ladipo DD, et al.: The powder flow and compact mechanical properties of two recently developed matrix-forming polymers. J Pharm Pharmacol. 2001; 53(9): 1193-1199.
30. Hernandez-Lopez C, Martinez-Farnos L, Karhu D, et al.: Comparative bioavailability between two Tramadol once-daily oral formulations. Methods Find Exp Clin Pharmacol. 2006; 28(6): 373-378.